Venous thromboembolism in children with cystic fibrosis: Retrospective incidence and intrapopulation risk factors

Knight‐Perry, Jessica; Branchford, Brian R.; Thornhill, Dianne; Martiniano, Stacey L.; Sagel, Scott D.; Wang, Michael

doi:10.1016/j.thromres.2017.08.022

Cited by 13 publications

(16 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although the aetiology of VTE in patients with IBD is likely to be multifactorial, accumulating evidence exists that the presence of systemic inflammation triggers a hypercoagulable state 54,55 . This is supported by the fact that some other pro-inflammatory conditions are more commonly associated with development of hospital-acquired VTE in paediatric patients, such as cystic fibrosis, childhood cancer and systemic infection [56][57][58][59] . Interestingly, three cases involved VTEs at multiple locations, supporting the theory that systemic in addition to local factors contribute to thrombus formation 60 .…”

Section: Discussionmentioning

confidence: 93%

The Incidence and Characteristics of Venous Thromboembolisms in Paediatric-Onset Inflammatory Bowel Disease; a Prospective International Cohort Study Based on the PIBD-SETQuality Safety Registry

et al. 2021

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 93%

The Incidence and Characteristics of Venous Thromboembolisms in Paediatric-Onset Inflammatory Bowel Disease; a Prospective International Cohort Study Based on the PIBD-SETQuality Safety Registry

et al. 2021

View full text Add to dashboard Cite

show abstract

“…VTE in children with cystic fibrosis was recently studied at a single center and the incidence rate was found to be 53 VTE cases per 10,000 children with CF. Several inflammatory-specific risk factors for VTE were reported, including sinus disease, positive respiratory cultures, and elevated inflammatory markers such as erythrocyte sedimentation rate and CRP ( 7 ). A recent retrospective study of 116 adults with CF hospitalized for pulmonary exacerbations using a CVC demonstrated a 2.5% incidence of catheter-related VTE ( 77 ).…”

Section: Cystic Fibrosis (Cf)mentioning

confidence: 99%

“…It is important to consider the contributions of inflammation to VTE development in general, but also as it pertains to certain specific disease categories more commonly associated with development of hospital-acquired VTE (HA-VTE) in some patients. Surgery, ( 1 – 3 ) obesity, ( 4 ) cystic fibrosis, ( 5 – 7 ) sepsis, ( 8 – 10 ) systemic infection, ( 11 , 12 ) cancer, ( 13 – 15 ) inflammatory bowel disease, ( 16 – 18 ), and lupus ( 19 – 22 ) are clinical VTE risk factors that may modulate thrombosis through inflammatory mediators. Understanding the role of inflammation in these particular clinical situations may not only help determine the optimal management but may also aid in the development of future preventative strategies, since current anticoagulation treatment regimens are not designed to inhibit inflammation ( 23 ).…”

mentioning

confidence: 99%

The Role of Inflammation in Venous Thromboembolism

2018

Self Cite

View full text Add to dashboard Cite

Venous thromboembolism (VTE), comprising deep vein thrombosis (DVT), and pulmonary embolism (PE), is becoming increasingly recognized as a cause of morbidity and mortality in pediatrics, particularly among hospitalized children. Furthermore, evidence is accumulating that suggests the inflammatory response may be a cause, as well as consequence, of VTE, but current anticoagulation treatment regimens are not designed to inhibit inflammation. In fact, many established clinical VTE risk factors such as surgery, obesity, cystic fibrosis, sepsis, systemic infection, cancer, inflammatory bowel disease, and lupus likely modulate thrombosis through inflammatory mediators. Unlike other traumatic mechanisms of thrombosis involving vascular transection and subsequent exposure of subendothelial collagen and other procoagulant extracellular matrix materials, inflammation of the vessel wall may initiate thrombosis on an intact vein. Activation of endothelial cells, platelets, and leukocytes with subsequent formation of microparticles can trigger the coagulation system through the induction of tissue factor (TF). Identification of biomarkers to evaluate VTE risk could be of great use to the clinician caring for a patient with inflammatory disease to guide decisions regarding the risk:benefit ratio of various types of potential thromboprophylaxis strategies, or suggest a role for anti-inflammatory therapy. Unfortunately, no such validated inflammatory scoring system yet exists, though research in this area is ongoing. Elevation of C-reactive protein, IL-6, IL-8, and TNF-alpha during a response to systemic inflammation have been associated with increased VTE risk. Consequent platelet activation enhances the prothrombotic state, leading to VTE development, particularly in patients with other risk factors, most notably central venous catheters.

show abstract

“…This can be related to the decreased incidence of dyslipidemia in these patients. Nevertheless, a higher incidence of venous thromboembolism was found in children with CF [ 18 ].…”

Section: Introductionmentioning

confidence: 89%